Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease

被引:13
|
作者
Charatcharoenwitthaya, Phunchai [1 ]
Karaketklang, Khemajira [1 ]
Aekplakorn, Wichai [2 ]
机构
[1] Mahidol Univ, Fac Med, Dept Med, Div Gastroenterol,Siriraj Hosp, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Dept Community Med, Ramathibodi Hosp, Bangkok, Thailand
关键词
Non-alcoholic fatty liver disease; Sarcopenia; Muscle strength; Body mass index; Mortality; INSULIN-RESISTANCE; GRIP STRENGTH; LEAN PATIENTS; SARCOPENIA; RISK; NONOBESE; EPIDEMIOLOGY; PREVALENCE; MORBIDITY; FIBROSIS;
D O I
10.1002/jcsm.13001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Whether adiposity and muscle function are associated with mortality risk in patients with non-alcoholic fatty liver disease (NAFLD) remains unknown. We examine the independent and combined associations of body mass index (BMI) and muscle strength with overall mortality in individuals with NAFLD. Methods We analysed data from 7083 participants with NAFLD in the Thai National Health Examination Survey and their linked mortality. NAFLD was defined using a lipid accumulation product in participants without significant alcohol intake. Poor muscle strength was defined by handgrip strength of <28 kg for men and <18 kg for women, according to the Asian Working Group on Sarcopenia. The Cox proportional-hazards model was constructed to estimate the adjusted hazard ratio (aHR) for overall mortality. Results The mean age was 49.3 +/- 13.2 years, and 69.4% of subjects were women. According to the Asian-specific criteria, 1276 individuals (18.0%) were classified as lean NAFLD (BMI 18.5-22.9 kg/m(2)), 1465 (20.7%) were overweight NAFLD (BMI 23-24.9 kg/m(2)), and 4342 (61.3%) were obese NAFLD (BMI >= 25 kg/m(2)). Over 60 432 person-years, 843 participants died. In Cox models adjusted for physiologic, lifestyle, and comorbid factors, individuals with lean NAFLD [aHR 1.18, 95% confidence interval (CI): 0.95-1.48; P = 0.138] and subjects with overweight NAFLD (aHR 1.28, 95% CI: 0.89-1.84; P = 0.158) had mortality risk estimates similar to their obese counterparts, whereas participants with lower handgrip strength had significantly higher mortality risk than those with higher handgrip strength in men and women. Compared with obese individuals with the highest handgrip strength, elevated mortality risk was observed among men (aHR 3.21, 95% CI: 1.35-7.62, P = 0.011) and women (aHR 2.22, 95% CI, 1.25-3.93, P = 0.009) with poor muscle strength. Among men, poor muscle strength was associated with increased risk of mortality with obese NAFLD (aHR 3.94, 95% CI, 1.38-11.3, P = 0.013), overweight NAFLD (aHR 2.93, 95% CI, 1.19-7.19, P = 0.021), and lean NAFLD (aHR 2.78, 95% CI, 0.93-8.32, P = 0.065). Among women, poor muscle strength was associated with increased mortality risk with obese NAFLD (aHR 2.25, 95% CI, 1.06-4.76, P = 0.036), overweight NAFLD (aHR 1.69, 95% CI, 0.81-3.51, P = 0.153), and lean NAFLD (aHR 2.47, 95% CI, 1.06-5.73, P = 0.037). Conclusions In this nationwide cohort of individuals with NAFLD, muscle strength, but not BMI, was independently associated with long-term overall mortality. Measuring handgrip strength can be a simple, non-invasive risk stratification approach for overall mortality in patients with NAFLD.
引用
收藏
页码:2393 / 2404
页数:12
相关论文
共 50 条
  • [1] Body Mass Index as a Predictor of Mortality for Severe Non-alcoholic Fatty Liver Disease
    Davis-Yadley, Ashley H.
    Lipka, Seth
    Shahzad, Ghulamullah
    Clayton, Steven B.
    Kumar, Ambuj
    Pathak, Elizabeth
    Kemmer, Nyingi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S855 - S856
  • [2] Body Composition and Muscle Mass in Patients with Non-Alcoholic Fatty Liver Disease: A Radiological Study Computed Tomography Analysis of Body Composition in Patients with Non-Alcoholic Fatty Liver Disease
    Foje, Nathan
    Khandalavala, Birgit
    Oliveto, Jennifer
    Rochling, Fedja
    Geske, Jennene
    FASEB JOURNAL, 2017, 31
  • [3] Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
    Hao, Xuan-Yu
    Zhang, Kai
    Huang, Xing-Yong
    Yang, Fei
    Sun, Si-Yu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (07) : 636 - 643
  • [4] Body mass index and waist circumference in non-alcoholic fatty liver disease
    Rocha, R
    Cotrim, HP
    Carvalho, FM
    Siqueira, AC
    Braga, H
    Freitas, LA
    JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2005, 18 (05) : 365 - 370
  • [5] Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease
    Rigor, Joana
    Vasconcelos, Raquel
    Lopes, Rogerio
    Moreira, Teresa
    Barata, Pedro
    Martins-Mendes, Daniela
    MINERVA GASTROENTEROLOGY, 2023, 69 (03): : 374 - 381
  • [6] Non-Alcoholic Fatty Liver Disease and Obesity: Not All About Body Mass Index
    Pagadala, Mangesh R.
    McCullough, Arthur J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (12): : 1859 - 1861
  • [7] IMPACT OF BODY MASS INDEX ON DISEASE PROGRESSION AND OUTCOMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.
    Biswas, Sagnik
    Vaishnav, Manas
    Swaroop, Shekhar
    Sheikh, Sabreena
    Arora, Umang
    Pathak, Piyush
    Farooqui, Naba
    Das, Prasenjit
    Yadav, Rajni
    Gamanagatti, Shivanand
    Shalimar
    HEPATOLOGY, 2022, 76 : S701 - S702
  • [8] Normal body mass index as a risk factor for osteopenia in patients with non-alcoholic fatty liver disease patients
    Farrugia, Maria
    Gerada, Martina
    Bonello, John
    Gauci, James Mario
    Pullicino, Richard
    Gerada, Jurgen
    HEPATOLOGY, 2015, 62 : 1303A - 1303A
  • [9] Low skeletal muscle mass is a potential risk factor for lean non-alcoholic fatty liver disease in patients with non-alcoholic fatty liver disease
    Kang, Min Kyu
    Park, Jung Gil
    JOURNAL OF HEPATOLOGY, 2021, 75 : S550 - S550
  • [10] Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index
    Petta, S.
    Di Marco, V.
    Camma, C.
    Butera, G.
    Cabibi, D.
    Craxi, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (12) : 1350 - 1360